Effects of Sacubitril/Valsartan on Blood Pressure and Proteinuria in Hypertensive Patients With Chronic Kidney Disease
The Journal of Clinical Hypertension · 2025
DOI: 10.1111/jch.70089 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Hypertension, 2025. Verfasst von Maki Murakoshi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Aminobutyrates, Proteinuria, Valsartan, Hypertension. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The effects of the angiotensin receptor–neprilysin inhibitor sacubitril/valsartan (Sac/Val) on blood pressure (BP) and proteinuria in patients with advanced chronic kidney disease and hypertension remain unclear. This retrospective study evaluated the effect of Sac/Val on BP, the urinary protein‐to‐creatinine ratio (UPCR), and the estimated glomerular filtration rate (eGFR) in 66 patients with hypertension and proteinuria (UPCR ≥ 0.15 g/g) who received renin–angiotensin system inhibitors at 1, 3, and 6 months. At baseline, the median eGFR and UPCR were 28.4 mL/min/1.73 m 2 and 1.18 g/g, respectively. Significant reductions in systolic and diastolic BP, the eGFR, and the UPCR were observed over time ( p values ranged from 0.03 to < 0.0001). At 1 month, 59% of patients showed a transient increase in the UPCR, and 21% had a ≥10% decline in the eGFR, with both metrics returning closer to baseline by 6 months. The percent change in the UPCR at 1 month was positively correlated with the percent change in the eGFR ( r = 0.55, p < 0.0001). In conclusion, Sac/Val showed considerable BP‐lowering efficacy even in patients with impaired renal function and proteinuria. Early changes in the eGFR were positively correlated with changes in the UPCR, and patients with an early decline in the eGFR or an increase in proteinuria did not experience further worsening.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.
- Division of Kidney Health and Aging, The Center for Integrated Kidney Research and Advance, Shimane University Faculty of Medicine, Shimane, Japan.
ORCID-Profile: Maki Murakoshi
Zitieren
APA
Murakoshi, M., Kobayashi, T., Kihara, M., Ueda, S., Suzuki, Y., & Gohda, T. (2025). Effects of Sacubitril/Valsartan on Blood Pressure and Proteinuria in Hypertensive Patients With Chronic Kidney Disease. The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.70089
Vancouver
Murakoshi M, Kobayashi T, Kihara M, Ueda S, Suzuki Y, Gohda T. Effects of Sacubitril/Valsartan on Blood Pressure and Proteinuria in Hypertensive Patients With Chronic Kidney Disease. The Journal of Clinical Hypertension. 2025. doi:10.1111/jch.70089
BibTeX
@article{Murakoshi2025,
author = {Murakoshi, Maki and Kobayashi, Takashi and Kihara, Masao and Ueda, Seiji and Suzuki, Yusuke and Gohda, Tomohito},
title = {Effects of Sacubitril/Valsartan on Blood Pressure and Proteinuria in Hypertensive Patients With Chronic Kidney Disease},
journal = {The Journal of Clinical Hypertension},
year = {2025},
doi = {10.1111/jch.70089}
}
EUVIMED